This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

FPI-1465

Fedora Pharmaceuticals Inc.

Drug Names(s): FPI-1465

Description: FPI-1465 is a ß-Lactamase inhibitor that has the ability to re-sensitize resistant bacteria to currently used ß-lactam antibiotics.

Deal Structure: Fedora and NAEJA
In March 2012, Fedora Pharmaceuticals announced the Companys incorporation and in-license of exclusive worldwide rights to a family of beta-lactamase inhibitors (BLIs) discovered by scientists at NAEJA Pharmaceuticals.

Partners: NAEJA Pharmaceuticals Inc.


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug